Cullgen
Cullgen is a biopharmaceutical company specializing in the development of first-in-class medicines for cancer and other serious diseases, utilizing its proprietary uSMITE™ technology platform.
Services
Cullgen specializes in developing first-in-class medicines for diseases that lack effective treatments. Their innovative use of proprietary technology, uSMITE™, features novel E3 ligands which enable the creation of robust protein degraders. These degraders are designed specifically to treat cancer and other debilitating diseases, targeting proteins involved in disease pathways to provide therapeutic solutions.
Technology Platform
Cullgen's technological foundation is built on their proprietary uSMITE™ platform, which leverages novel E3 ligands. This technology underpins their development of protein degraders that target and break down disease-associated proteins. This approach allows Cullgen to create effective treatments for complex diseases that thus far have resisted traditional therapeutic approaches.
Location and Facilities
Cullgen is headquartered at 12730 High Bluff Drive, Suite 250, San Diego, CA 92130, USA. Additionally, they maintain a significant presence in Shanghai, China, located at 230 Chuan Hong Road, Building 6, Pu Dong New Area, Shanghai, 201202. These locations enable Cullgen to leverage global resources and talent in their mission to develop cutting-edge medical treatments.
Clinical Trials
Cullgen has initiated a Phase I/II clinical trial for CG001419, a pioneering TRK protein degrader designed for cancer treatment. This clinical trial represents a critical step in assessing the efficacy and safety of CG001419 in treating cancer patients, demonstrating Cullgen's commitment to advancing medical science through rigorous clinical research.
Awards and Recognitions
In 2023, Cullgen was honored with the LES Deals of Distinction Award in collaboration with Astellas. This award reflects the company's contributions to the field of biotechnology and the impact of their innovative partnerships in advancing therapeutic solutions for challenging diseases.